Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 7;11(4):279.
doi: 10.3390/jpm11040279.

Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials

Hou-Ren Tsai  1 , Jing-Wun Lu  2 , Li-Yu Chen  3 , Tai-Li Chen  1   4
Affiliations
Review

Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials

Hou-Ren Tsai et al. J Pers Med. .

Abstract

Janus kinase (JAK) inhibitors are promising treatments for atopic dermatitis (AD). The aim of this study was to assess the efficacy and safety of JAK inhibitors for AD treatment via the "Grading of Recommendations Assessment, Development, and Evaluation" approach. We identified 15 randomized controlled trials comparing oral or topical JAK inhibitors against placebo to treat AD. A random-effects meta-analysis was performed, and the numbers-needed-to-treat (NNTs)/numbers-needed-to-harm (NNHs) were calculated. Patients treated with JAK inhibitors were associated with higher rates of achieving eczema area and severity index-75 (rate ratio (RR): 2.84; 95% confidence interval (CI): 2.20-3.67; I2: 38.9%; NNT = 3.97), Investigator's Global Assessment response (RR: 2.99; 95% CI: 2.26-3.95; I2: 0%; NNT = 5.72), and pruritus numerical rating scale response (RR: 2.52; 95% CI: 1.90-3.35; I2: 39.4%; NNT = 4.91) than those treated with placebo. Moreover, patients treated with JAK inhibitors had a higher risk of treatment-emergent adverse events (RR: 1.14; 95% CI: 1.02-1.28; I2: 52%; NNH = 14.80) but not adverse events leading to drug discontinuation. According to the evidence-based results, JAK inhibitors are potentially effective strategies (certainty of evidence: "moderate") for treating AD with tolerable side effects (certainty of evidence: "low"). Nevertheless, long-term follow-up is required.

Keywords: JAK inhibitors; atopic dermatitis; eczema; evidence-based medicine; immune-mediated skin diseases; meta-analysis; skin conditions and systemic inflammatory diseases; systematic review; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Association of Janus kinase (JAK) inhibitors versus placebo achieving at least a 75% improvement in Eczema Area and Severity Index (EASI) score from the baseline (EASI-75 response). CI, confidence interval.
Figure 2
Figure 2
Association of Janus kinase (JAK) inhibitors versus placebo achieving of an Investigator Global Assessment (IGA) of 0 (clear) or 1 (almost clear) with at least a two-point reduction from the baseline (IGA response). CI, confidence interval.
Figure 3
Figure 3
Association of Janus kinase (JAK) inhibitors versus placebo achieving at least a four-point improvement in pruritus Numerical Rating Scale (NRS) score from the baseline (pruritus-NRS response). CI, confidence interval.
See this image and copyright information in PMC

References

    1. Silverberg J.I., Hanifin J.M. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. J. Allergy Clin. Immunol. 2013;132:1132–1138. doi: 10.1016/j.jaci.2013.08.031. - DOI - PubMed
    1. Bylund S., von Kobyletzki L.B., Svalstedt M., Svensson Å. Prevalence and incidence of atopic dermatitis: A systematic review. Acta Derm. Venereol. 2020;100:adv00160. doi: 10.2340/00015555-3510. - DOI - PMC - PubMed
    1. Langan S.M., Irvine A.D., Weidinger S. Atopic dermatitis. Lancet. 2020;396:345–360. doi: 10.1016/S0140-6736(20)31286-1. - DOI - PubMed
    1. Kaufman B.P., Guttman-Yassky E., Alexis A.F. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp. Dermatol. 2018;27:340–357. doi: 10.1111/exd.13514. - DOI - PubMed
    1. Nettis E., Ortoncelli M., Pellacani G., Foti C., Di Leo E., Patruno C., Rongioletti F., Argenziano G., Ferrucci S.M., Macchia L., et al. A multicenter study on the prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J. Investig. Allergol. Clin. Immunol. 2020;30:448–450. doi: 10.18176/jiaci.0519. - DOI - PubMed

LinkOut - more resources